Publications by authors named "Thomas Engber"

Claim this Profile
S
Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy.
Guido Cavaletti, Chiara Pizzamiglio, Albert Man, Thomas M Engber, Cristoforo Comi

Cancers (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.
Todd Bosanac, Robert O Hughes, Thomas Engber, Rajesh Devraj, Andrew Brearley

Brain· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small Molecule SARM1 Inhibitors Recapitulate the SARM1 Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate.
Robert O Hughes, Todd Bosanac, Xianrong Mao, Thomas M Engber, Aaron DiAntonio

Cell Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons.
Yo Sasaki, Thomas M Engber, Robert O Hughes, Matthew D Figley, Tong Wu

Exp Neurol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration.
Raul Krauss, Todd Bosanac, Rajesh Devraj, Thomas Engber, Robert O Hughes

Trends Pharmacol Sci· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H Weinreb, Leslie Williams, Thomas Engber

Nature· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H Weinreb, Leslie Williams, Thomas Engber

Nature· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.
James E Dowling, Jeffrey T Vessels, Serajul Haque, He Xi Chang, Kurt van Vloten, Thomas Engber

Bioorg Med Chem Lett· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of combined treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord injury.
Benxiu Ji, Mingwei Li, Stephane Budel, R Blake Pepinsky, Lee Walus, Thomas M Engber

Eur J Neurosci· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Chi B Vu, Deborah Pan, Bo Peng, Gnanasambandam Kumaravel, Glenn Smits, Thomas Engber

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.
Gang Yao, Serajul Haque, Li Sha, Gnanasambandam Kumaravel, Joy Wang, Thomas M Engber

Bioorg Med Chem Lett· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
Hairuo Peng, Gnanasambandam Kumaravel, Gang Yao, Li Sha, Joy Wang, Thomas M Engber

J Med Chem· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.
Chi B Vu, Deborah Pan, Bo Peng, Li Sha, Gnanasambandam Kumaravel, Thomas Engber

Bioorg Med Chem Lett· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.
Chi B Vu, Pamela Shields, Bo Peng, Gnanasambandam Kumaravel, Xiaowei Jin, Thomas Engber

Bioorg Med Chem Lett· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Chi B Vu, Bo Peng, Gnanasambandam Kumaravel, Glenn Smits, Xiaowei Jin, Thomas Engber

J Med Chem· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple actions of systemic artemin in experimental neuropathy.
Luis R Gardell, Ruizhong Wang, Chris Ehrenfels, Michael H Ossipov, Anthony J Rossomando, Thomas Engber

Nat Med· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy.
Nigel A Calcutt, Karen L Allendoerfer, Andrew P Mizisin, Alicia Middlemas, Jason D Freshwater, Thomas M Engber

J Clin Invest· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting forms of Sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model.
R Blake Pepinsky, Renee I Shapiro, Shaoshan Wang, Abhijit Chakraborty, Alan Gill, Thomas M Engber

J Pharm Sci· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis